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Abstract
The Signature Series Symposium “Cellular Therapies for Orthopaedics and Musculoskeletal Disease Proven and Unproven
Therapies—Promise, Facts and Fantasy” was held as a pre-meeting of the 26th International Society for Cellular Therapy
(ISCT) annual congress in Montreal, Canada, May 2, 2018. This was the first ISCT program that was entirely dedicated to the
advancement of cell-based therapies for musculoskeletal diseases. Cellular therapies in musculoskeletal medicine are a source of
great promise and opportunity. They are also the source of public controversy, confusion and misinformation. Patients, clini-
cians, scientists, industry and government share a commitment to clear communication and responsible development of the
field. Therefore, this symposium convened thought leaders from around the world in a forum designed to catalyze communica-
tion and collaboration to bring the greatest possible innovation and value to patients with musculoskeletal conditions.Correspondence:George F. Muschler, MD, Department of Orthopaedic Surgery and Biomedical Engineering, Cleveland Clinic, 9500 Euclid Avenue, Cleve-
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The following areas were identified as key priorities
for communication and action: (i) understanding
market forces and trends; (ii) confronting the issue of
extensive direct-to-patient marketing of unproven
therapies; (iii) defining the value of current therapies
for patients and payers; (iv) defining constructive
regulatory paths and priorities; (v) defining industry
and clinical standards; (vi) clarity and transparency
in publications, regulatory affairs and marketing
claims; (viii) enabling clinical networks and regis-
tries; and (ix) identifying knowledge gaps and inno-
vation opportunities.
These topics were addressed by a series of ses-
sions and speakers. The content below provides a
focused synopsis of the outcome of each of these ses-
sions and associated panel discussions.Market trends and market practices
Provenunproven therapies, Massimo Dominici, MD
The current spectrum of cellular therapies can be
divided objectively into two general models. On
one end are precisely characterized cellular medical
therapies provided to patients by intellectually rig-
orous caregivers with appropriate informed consent
(e.g., first in humans, phase 1, phase 2 and phase 3
trials). Studies of this kind have been the scientific
and ethical foundation of medical innovation and
new medical/surgical treatments for decades. On
the other end of the spectrum are a broad range of
unregulated cell and tissue-based products and
medical procedures for which claims of efficacy are
made with little or no scientific evidence. These
therapies are often offered to patients on a cash-
only basis and are provided to patients without
clarity in the informed consent. There is broad
consensus that this unproven cellular therapy
(UCT) end of the spectrum represents a large and
growing, but unjustified, business model [1].
The size of the UCT world-wide business has
been estimated to be around 2.4 billion US dollars
(USD)/y [16]. This market touches upon almost
every medical discipline, particularly neurological
and musculoskeletal conditions [6]. However, UCTs
are not embraced or endorsed by leading profes-
sional societies, and care is often provided by practi-
tioners who are not board certified in the relevant
medical specialties.
Several factors seem to be driving UCT, includ-
ing the following: (i) the unmet demand for effective
therapies for many common diseases. For example,
in the case of osteoarthritis of the knee, many
patients reach a point where conventional therapies
have failed to control symptoms, but the symptomsare not so severe that joint replacement is considered
desirable; this results in a large demand and placed
hope for new injectable therapies; (ii) enormous pub-
lic hope and expectations, particularly for long-antic-
ipated “stem cell therapies” reflecting inadequate
public education, (iii) poor marketing communica-
tion, if not deliberate miscommunication regarding
the nature and track record of individual therapies;
(iv) the wide availability of technology (centrifuges,
culture systems, reagents etc.), and (v) patient ability
and willingness to pay for therapies out of pocket for
care that is not covered by traditional payers or
health care systems.
The UCT strategies that are marketed to patients
frequently make reference to legitimate scientific
developments, and imply directly or indirectly that
they are aligned with or based on advancements in
the field. This time-honored marketing strategy is
used to establish the perception of quality and value
by association. However, this is not reality. Both
patient information and product design and specifi-
cations are rarely more than business decisions based
on cost and regulatory loopholes, without real contri-
butions of innovation, product validation or rigorous
clinical evidence of efficacy.
Social media, regulatory gaps and loopholes and
the legitimate ethical and liability concerns of larger
established companies, which might normally be
required to bring new therapies to market, have
opened the door for small targeted clinics and even
small manufacturers to rapidly bring forward busi-
ness models in niche markets on a “pay cash to be
treated” basis, without performing controlled clinical
studies.
Clinics often adopt the “charitable dress,” mean-
ing “we care enough about you to cut through the
red tape that keeps greedy rich people in big pharma-
ceutical companies and timid less talented traditional
doctors in ivory tower institutions from offering you
these therapies.” However, the environment of
direct-to-consumer marketing and disinformation
presents substantial risk for patients. Physical harm
can occur, as illustrated in several high-profile inci-
dences [7,8]. However, the frequency of true and
direct harm may be small. More likely is that a
patient loses time and money and experiences added
emotional frustration of investing in something that
later might prove to be ineffective.
The professional literature has begun to address
the challenge of UCT more assertively in the past
few years [9]. This has been picked up by a number
of attentive and dedicated journalists who have
begun to contribute greatly to address deficits in
public knowledge and awareness related to “stem
cells” and other unproven cellular and acellular ther-
apies [10].
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access to promising investigational therapies. There
is also a spirited debate over how this can best be
accomplished in a way that serves both current and
future patients in an environment of safety and
respect. “SMAC”, which stands for Science evi-
dence, rigorous Manufacturing process, Accurate
information for patients and Consistent product
(content and delivery), is a clearly articulated, albeit
greatly simplified acronym, that can be applied to
guide this challenge. SMAC puts data, quality,
transparency and consistency squarely at the center
of the discussion, which may be considered mini-
mum requirements for progress. SMAC embraces
traditional clinical trials, compassionate use, clinical
outcomes networks, as well as the concept of well-
designed clinical registries and biorepositories. How-
ever, these approaches demand rigorous design, exe-
cution (communication, recruiting, quality care,
data collection, follow-up), statistical support and
ethical oversight.
We already have examples of evolution in policy
designed to facilitate compassionate use, hospital
exemption and priority pathways for clinical imple-
mentation. The recent Food and Drug Administra-
tion (FDA) position paper offers guidance on ways
to get an investigational product into settings where
they may benefit a large number of patients [1113].
Legislation has also been used in some countries to
support medical innovation based on cell therapies.
For example, Japan passed a law to stimulate the
regenerative medicine industry by conditional appro-
vals. The 21st Century Cures Act in the USA also
has provisions designed to accelerate approvals of
cell therapies and the recent “right-to-try” law to
provide products to terminally ill patients. However,
these efforts should not be interpreted as a relaxation
toward deregulation, nor a tolerance for loose con-
trols in manufacturing platforms or compromises in
patient safety on the altar of innovationHope, hype, investment and rewards, Nicolas Piuzzi,
MD
Between 1994 and 2016 more than 23 billion USD
have been invested in stem cell companies. More
than 18 billion USD has been invested between
2011 through 2016 alone [14]. However, this growth
has not been matched by similar growth rates in
earnings, reflecting a field that is only emerging from
infancy [14].
Direct-to-consumer marketing of unproven cellu-
lar therapies marketed as “stem cells” is a well-
known phenomenon. Musculoskeletal conditions,
particularly osteoarthritis (OA) of the knee, are
among the most frequent conditions for which thesetherapies are marketed. A recent publication aggre-
gated the claims of “stem cell” clinics, suggesting
that a mean of 80% of the patients have “good
results” or “symptomatic improvement” [15]. How-
ever, there is a substantial gap between these claims
and published literature [15].
Another report examined messaging related to
cell-based therapies for musculoskeletal conditions
on social media and found that these messages were
dominated by businesses that portray an almost
exclusively positive tone, without providing a “fair
balance” on the risks, benefits and limitations,
reflecting an environment of hype that contributes to
public misunderstanding related to the extent to
which efficacy has been documented [16].
While efficacy remains in question, the volume of
reporting on limited trials of autogenous therapies
for OA of the knee, focal cartilage defects of the knee
and osteonecrosis do not suggest a substantial safety
concern in current practice. However, the quality
of the published data is limited and there is a high
risk of reporting bias. The current literature is
highly inconsistent with respect to reporting
standards. There is a critical need for refinement
of definitive disease-specific clinical indications
and standardization of reporting related to cell
sourcing, cell characterization, use of adjuvant
therapies, assessment of outcomes and use of
appropriate controls [1722].Allograft bone graft matrices with viable cells, Marc
Long, PhD
The variable quality, limited availability, inconsistent
handling properties and donor site morbidity associ-
ated with the harvest of autograft bone has led to the
development of a broad range of allogeneic and syn-
thetic bone graft matrices (fibers, chips, powders,
blocks) and a substantial track record of safety and
efficacy. The value of adding osteogenic cells to a
matrix has been demonstrated (e.g., from autoge-
nous local bone or bone marrow aspirate) in many
studies [2327]. In fact, several current synthetic
matrices are approved for use only when combined
with autogenous marrow.
The value of adding cells has been reported by
pre-clinical data, suggesting that allograft cells can
be transplanted with low risk and possible efficacy
[28], stimulating the concept of fabricating allograft
bone graft materials with viable cells (BGMVCs). In
these materials, living cells are maintained during
processing and cryopreservation of human tissues
[29]. In theory, therefore, BGMVCs provide the
combination of osteoconduction (matrix for cell
attachment and migration), osteoinduction (bioac-
tive factors intrinsic to bone matrix) and osteogenic
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with bone-forming potential).
Donated human tissues are processed in accor-
dance with FDA and American Association of Tissue
Banks (AATB) requirements to generate BGMVCs.
There are now several commercially available
BGMVCs, which have different donor-screening cri-
teria, processing techniques and formulations. These
differences, as well as differences between donors,
may result in variation in biological quality, handing
properties and regulatory status as Human Cellular
and Tissue Products (HCT/Ps). Most follow FDA
regulations published in 21 Code of Federal Regula-
tions (CFR) Part 1271 Human Cells, Tissues, and
Cellular and Tissue-Based Products (HCT/Ps) and
meet all required criteria for 361 HCT/Ps [30].
However, some BGMVCs have been found to
involve more than “minimal manipulation” and,
therefore, do not meet all 361 HCT/Ps criteria.
These must be regulated as drugs or biological prod-
ucts. BGMVCs may also vary in the viability, num-
ber and potency of the osteogenic cells present in the
matrix.
Level I evidence to suggest that inclusion of via-
ble cells improves efficacy is currently lacking. How-
ever, some large prospective and retrospective
clinical cohort studies for one BGMVC suggest
promise (spinal fusion rates >90% at 1-year follow-
up) [3133]. Appropriately controlled clinical trials
are needed.The good news and bad news in current
product/therapy domains
Bone regeneration, George Muschler, MD
Bone healing and bone regeneration rely on general-
izable tissue engineering approaches [3436]. Bone
regeneration represents one of the most successful
domains of musculoskeletal care. Orthopedic sur-
geons have access to a withering array of scaffold
materials for bone regeneration (more than 70 exist-
ing products). These materials fill voids and prevent
the encroachment of other tissues into a region where
bone is desired. In general, scaffolds provide a
porous interconnected surface that enables revascu-
larization and the attachment and migration of bone-
forming cells throughout the desired tissue volume
(osteoconduction). Matrices can provide soluble or
tethered factors that enhance the proliferation, dif-
ferentiation and survival of osteogenic cells (osteoin-
duction). In many cases, cell transplantation is not
required to accomplish successful bone regeneration
because the local tissue environment provides a suffi-
cient population of osteogenic stem/progenitor cells.
In those cases, scaffolds or inductive factors simply“target” the local stem/progenitor population. How-
ever, in some settings (for example, segmental frac-
tures where bone and periosteum is missing, fracture
non-unions, irradiated tissue beds, sites compro-
mised by scarring from previous infection or injury,
revision spine fusions [3740]), the success of bone
regeneration is limited by a suboptimal tissue bed
and local progenitor pool. In these settings, strategies
to enhance bone regeneration require a strategy for
sourcing osteogenic stem and progenitor cells. The
local delivery of “homing” signals has been consid-
ered, but the most effective strategies to date involve
the harvest of autogenous cells from a healthy tissue
location (e.g., cancellous bone, periosteum or bone
marrow from the pelvis or metaphyseal bone) and
“transplantation” of those cells to a site where bone
is desired. Transplantation will optimally involve a
step of concentration of the osteogenic cells (i.e.,
removing fluid volume such as serum) and selection
of the osteogenic stem/progenitor population (i.e.,
removing cells that do not contribute to tissue regen-
eration or that may inhibit or compete with the oste-
ogenic population, while selecting for or retaining
the osteogenic cells) [3436,4143].
The good news in bone regeneration is that the
vast majority of bone-healing challenges can be
addressed with success rates of more than 90% using
available strategies. The bad news is that, despite all
the available alternatives, the treatment failure rates
remain high in challenging settings, and develop-
ment has been stalled by three limitations.
The first limitation is that virtually all existing and
new bone grafting products seek approval through
the 510K mechanism. This means that they aspire to
be “substantially equivalent” to existing predicate
products. This may be viable if the cost is low and
handling and performance properties are desirable,
but it can be argued that developing additional 510K
products actually squanders research and develop-
ment (R&D) capital that would benefit patients
more if it were used to advance efficacy in complex
settings.
The second limitation is that the small and large
animal models that have been used to date have
essentially reached their “ceiling effect.” Segmental
defects of 5 cm in healthy young dogs, sheep and
goats can be healed with near 100% efficacy using
combinations of available scaffolds, growth factors
(i.e., bone morphogenetic protein [rhBMP-2]) and/
or processed autogenous cells. As a result, existing
models are ineffective as tools to measure further
improvement in efficacy. More rigorous models are
needed. The chronic caprine tibial defect (CCTD)
model has been developed to addresses this limita-
tion and to ‘‘raise the bar’’ for rigorous assessment of
bone-grafting strategies. The CCTD model includes
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teum, bone marrow reaming and local scar formation,
which are missing in traditional acute large animal
models, and offers an opportunity to examine advan-
ces in cell concentration, selection and transplantation
strategies, as well as advanced biomaterials [42].
Finally, the third limitation to the advancement
of bone regeneration therapies is the limited avail-
ability of post-marketing data through prospective
cohort registries and through prospective clinical tri-
als, which can only be adequately powered through
the coordination of clinical networks.Cartilage repair and regeneration, Christian Jorgensen,
MD, PhD and Cecilia Pascual-Garrido, MD
OA is a common and debilitating disease that affects
27 million people in the US [44,45]. Forecasts indi-
cate that by the year 2030, 25% of the adult US pop-
ulation, or nearly 67 million people, will have
symptomatic OA [46]. Furthermore, OA raised
aggregate annual medical care expenditures by
$185.5 billion USD [44,45].
Traditional OA treatments have focused on mod-
ifying symptoms of pain. What is needed is disease-
modifying treatments that restore lost cartilage tissue
or prevent cartilage degeneration.
A variety of cartilage repair and replacement
strategies have shown promise. These have included
the following: en bloc transplantation of autograft or
allograft osteochondral tissues [47,48], transplanta-
tion of culture-expanded cells beneath or within a
biological polymer (e.g., collagen or hyaluronan) or
synthetic matrix. The success of cell transplantation
will inevitably be dependent on the concentration,
prevalence, biological attributes and biological
potential of the cell population involved. However,
no consensus has evolved regarding the optimal
source of cells for cartilage repair, harvest or process-
ing techniques, or critical quality attributes (CQAs)
that predict future performance [49]. A particular
limitation in cell transplantation is selection of a cell
population that maintains an articular cartilage phe-
notype and does not undergo endochondral ossifica-
tion over time [4952].
Preparations of culture-expanded bone marrow
stromal cells (BMSCs; both autologous and alloge-
neic) have been assessed in many pre-clinical and
clinical study settings [18,21,48,53,54]. In addition
to contributing to the formation of chondrocytes,
BMSCs may have other functions derived from the
diversity of bioactive factors that they secrete, includ-
ing the following: hepatocyte growth factor (HGF),
transforming growth factor b (TGFb), fibroblast
growth factor (FGF) and vascular endothelial growth
factor (VEGF). Insulin-like growth factor (IGF)1,interleukin (IL)-6 and stanniocalcin-1 are essential
for apoptotic reversal in fibroblasts, whereas VEGF,
HGF and TGFb1 have been shown to protect endo-
thelial cells from apoptosis [55]. For example,
BMSCs may reduce scar tissue formation [56].
However, the heterogeneity and batch-to-batch vari-
ation in BMSCs are challenges. Moreover, clinical
studies vary widely with respect to clinical methodol-
ogy, inclusion of appropriate controls, cell dose
(range one million to 180 million cells per intra-artic-
ular injection), methods of cell expansion and char-
acterization and choice of carrier [17,19,20,57].
Despite the heterogeneity of BMSC preparations, in
aggregate, these studies suggest a reduction in pain
and improved function is possible using cellular
therapies. However, larger treatment effects and
improvement in reproducibility are needed before
regulatory approval, clinical adoption and reim-
bursement can be expected [58,59].
Several strategies are available to improve the effi-
cacy of BMSC or similar cellular therapies. For exam-
ple, cells might be activated before injection (e.g.,
using Rapamycin, which inhibits mammalian target of
rapamycin (mTOR) signaling and mimics interferon
stimulation) [60]. Alternatively, inhibition of Peroxi-
some Proliferator-Activated Receptor (PPAR) Beta/
Delta transcription factor may enhance anti-inflamma-
tory effects [61]. Cell combinations may be used (e.g.,
autologous chondrocytes with BMSCs) [62]. Knowl-
edge of CQAs that can be measured in vitro and pre-
dict in vivo efficacy have not been defined but are
critical to the long-term development of this approach.
The potential for disease-modifying osteoarthritis
drugs (DMOADs) that preserve cartilage in the set-
ting of early OA is opening up on several new fronts.
The strategy for use of these agents is linked to a
“personalized” patient-specific approach in which
biological or gene expression markers are used to
identify joints at risk and justify pre-emptive inter-
vention, even before symptoms might justify current
invasive intervention approaches [63]. Several bio-
logical targets have been evaluated (e.g,. inhibition
of IL1b or Nerve growth factor (NGF) receptor),
and may reduce pain, but thus far with no effect on
OA progression [64,65].
Future therapeutics may consider both the
patient’s genetic susceptibility as well as environmen-
tal risk factors (e.g., injury). Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR)
genome engineering technology enables strategies
like Stem cells Modified for Autonomous Regenera-
tive Therapy (SMART) to selectively reduce inflam-
mation caused by arthritis and other chronic
conditions through local production of anti-inflam-
matory molecules. If durable engraftment can be
obtained, such cells may be used like a long-term
1386 N.S. Piuzzi et al.vaccine-limiting progression of OA from early-stage
disease [66].
One of the biggest limitations in establishing the
safety and efficacy of these new cartilage therapies is
the cost of clinical trials, particularly randomized
controlled phase 2 and 3 trials (RCTs). The organi-
zation of large multicenter registries for cartilage
repair may be critical to reducing these barriers to
progress. Given the well-documented natural history
of OA, and its progression to expensive interventions
of arthroplasty surgery, prospective cohort studies
may provide a practical and rigorous means to
improve clinical research generally and set the stage
for an alternative approval pathway [67].
Effective clinical trials of DMOADs will focus on
early OA with the goal of limiting progression of OA
(e.g., reducing inflammation and bone edema). The
musculoskeletal community has not yet defined con-
sensus of the most appropriate methodology for such
trials. However, it is likely that trials will include
both clinical measures of pain and function as well as
imaging to measure structural attributes of the joint
(e.g., cartilage thickness/volume, cartilage surface
integrity, meniscus volume, effusion volume and
synovial thickness).Tendon repair and regeneration, Scott Rodeo, MD
Cellular therapies for tendon repair are less well
developed than for bone and cartilage [68]. The pro-
cess of determining the optimal protocol for cell ther-
apy for tendon disorders must begin by defining the
underlying tendon pathology being treated. The
optimal cell therapy for treatment of chronic, degen-
erative tendinopathy will likely differ from the
approach needed for repair of an acute tendon tear.
Moreover, the anatomic location of tendon repair
will vary, along with the biology. Repair may be ten-
don-to-tendon (e.g., flexor tendon repair in the hand
or Achilles tendon repair), but other clinical settings
require tendon-to-bone repair (such as in rotator
cuff tendon repair).
Further information is needed about the cellular
and molecular mechanisms of tendon degeneration
and healing in each of these settings, to identify the
rate-limiting steps and key biological targets that
may be addressed using cell therapy [6974]. For
example, the optimal cell type and dose (concentra-
tion, volume, frequency) may be different in each
setting. In some settings, the goal may be to increase
tendon cell proliferation and to accelerate matrix
synthesis in a healing tendon repair. In other settings,
optimal methods may target the inhibition of matrix-
degrading proteases and inflammatory mediators in
a chronically degenerative tendon.There are important outstanding questions about
optimal timing and dosing of cell therapy. For exam-
ple, cell therapy may be most valuable if delivered at
the time of surgery. On the other hand, efficacy,
retention and survival may be better if delivered days
or weeks after injury or surgery. Furthermore, it is
possible that repeat cell dosing will optimize out-
come.
The tissue volume that requires repair is less
defined and more variable in the setting of tendon or
ligament repair than for bone and cartilage. Optimal
methods for delivery to optimize cell retention and
survival at the tendon repair site will likely be differ-
ent. A carrier vehicle may be required to localize the
cells to the repair site for a relevant period of time.
The microstructure, composition and chemistry of
such a carrier vehicle will inevitably affect the biolog-
ical activity of the implanted cells.
Like bone and cartilage therapies, robust clinical
studies, including prospective cohort studies and
multi-center registries, will be critical to assess and
optimize cellular therapy for treatment of degenera-
tive tendinopathy and surgical tendon repair.Muscle repair and regeneration, Johnny Huard, PhD
Muscle tissue contains progenitor populations that
can be stimulated to form new muscle tissue. How-
ever, muscle regeneration is frequently limited by scar
formation, rather than muscle regeneration [75].
Platelet-rich plasma (PRP) is an emerging biolog-
ical tool with particular relevance to the field of
regenerative medicine because it contains an abun-
dance of autologous growth factors and is easy to
obtain and manipulate. Although the use of PRP has
become an increasingly popular treatment option for
various musculoskeletal conditions, published clini-
cal results have been inconsistent. PRP contains
many important growth factors that may accelerate
tissue healing (including platelet-derived growth fac-
tor [PDGF], VEGF, IGF and TGF-b1, among
many others). However, PRP also contains large
quantities of substances that are known to pro
mote further inflammation and subsequent tissue
damage (such as inflammatory cytokines, reactive
oxygen species [ROS], and matrix metalloprotei-
nases [MMPs]).
A combination of PRP injection and oral admin-
istration of losartan (an antifibrotic agent) has been
shown to enhance muscle healing by stimulating
muscle regeneration and angiogenesis and to prevent
fibrosis in contusion-injured skeletal muscle [75].
Muscle regeneration and muscle function were sig-
nificantly promoted with the combined PRP + losar-
tan treatment in contusion injuries created in the
tibialis anterior muscles of mice compared with the
Proceedings 1387other groups. Combined PRP+ losartan treatment
significantly decreased the expression of phosphory-
lated Smad2/3 and the development of fibrosis com-
pared with PRP treatment alone, and it increased
VEGF expression and the number of CD31-positive
cells compared with losartan treatment alone. Folli-
statin, a positive regulator of muscle growth, was
expressed at a higher level in the PRP+ losartan group
compared with the other groups. PRP+ losartan com-
binatorial therapy improved overall skeletal muscle
healing after muscle contusion injury by enhancing
angiogenesis and follistatin expression and by reduc-
ing the expression of phosphorylated Smad2/3 and
the development of fibrosis. These results suggest that
blocking the expression of TGF-b1 with losartan
improves the effect of PRP therapy on muscle healing
after a contusion injury [76].
Neutralizing TGF-b1’s action in PRP has also
been shown to improve muscle repair [76]. PRP was
isolated from in-bred Fisher rats. TGF-b1 neutrali-
zation antibody (Ab) was used to block the TGF-b1
within the PRP prior to injection. The effects of cus-
tomized PRP on muscle healing was tested on a car-
diotoxin (CTX)-induced muscle injury model,
proving that neutralizing TGF-b1 within PRP signif-
icantly promotes muscle regeneration while reducing
fibrosis. Not only did the neutralization reduce fibro-
sis, it enhanced angiogenesis, prolonged satellite cell
activation and recruited a greater number of M2
macrophages to the injury site, which also contrib-
uted to the efficacy that the customized PRP had on
muscle healing. These findings could contribute to
the development of biological treatments that aid in
the healing of skeletal muscle after injury [76,77].Intervertebral disc, Jerome Guicheux, PhD
Intervertebral disc (IVD) is the central player of
spine kinematics. Its degeneration is one of the major
causes of low back pain (LBP). Discogenic LBP is
primarily managed using pharmacological treat-
ments. Surgical procedures (fusion or disc replace-
ment) are reserved for severe debilitating LBP. To
clinically address LBP early in the degenerative cas-
cade of IVD, cell-based regenerative strategies could
offer less-invasive alternatives to spinal reconstruc-
tive surgery.
Different cell-based approaches have been pro-
posed [78]. First, the intradiscal injection of
undifferentiated MSCs, mostly from bone marrow
or adipose tissue, has been tested in pre-clinical
animal models with some success [79,80]. Several
clinical trials have described improvement in pain
but with no clear evidence of a structural effect
[81]. MSC therapies using a biomaterial cell car-
rier have more recently been considered (e.g., aninjectable hydrogel). A recent clinical trial reports
that this could be safe and well tolerated. Several
trials are ongoing [82].
Finally, the production of regenerative cells
derived from induced pluripotent stem cells (iPSCs)
is being considered. The generation of such engi-
neered IVD cells and their association with scaffold-
ing biomaterials mimicking the natural environment
of a healthy IVD holds great promise for IVD regen-
eration [83].Clinical adoption gap—value, regulations and
standards
Reporting standards for cell therapies, Nicolas S. Piuzzi,
MD
There have been many calls for standardization in
the field of cell-based therapies and in the treatment
of musculoskeletal diseases [17,1922,57,84,85].
Many standards exist for classification of disease,
biological and bioactive composition in tissues,
chemical reagents and materials. However, cur-
rently there is a dearth of standards for quantita-
tive identification and characterization of cell
populations and for methods of cell harvest, proc-
essing and fabrication.
Standards are essential for clear, precise and rig-
orous communication, and to allow reproducibility
in measurement and process management. Stand-
ards are usually established by authority, custom or
general consent, and provide models or rules for
measurement and reporting on the identity, quantity,
quality or purity of a material or the efficiency, effec-
tiveness or variability in a task or process.
The field of cell biology, especially related to cul-
ture-expanded cells, is filled with a confusing and
competing litany of names for various culture-
expanded cells and cell products. Names are fre-
quently coined arbitrarily and nomenclature is
frequently disconnected from the biology and iden-
tity of cells in native tissues or a specific and consis-
tent measure identifying phenotypic or functional
attribute. Moreover, publications vary widely with
respect to the relevant metrics of cell processing and
characterization that are reported: tissue source, iso-
lation/selection method, expansion conditions, sur-
face marker attributes, concentration, prevalence,
gene expression profile, morphological features, pro-
teome signature, etc. As a result, articles frequently
lack information that would be critical to enable
work to be repeated or effectively compared with
work by another investigator or laboratory.
However, progress in standards development and
use is being made. For example, the International
Society for Cellular Therapy (ISCT) committee on
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minimal criteria for defining the term MSC in an
attempt to advance communication in the field [86].
Standards for reporting are being proposed for PRP
preparations and isolation of bone marrowderived
populations [17,20,57,84,87]. Furthermore, validat-
ing assays that assess cellular composition and preva-
lence, concentration and biological potential of stem
and progenitor cells will be required as test methods
and analysis methods are developed. As an example,
the colony-forming efficiency unit assay, which
constitutes a key feature in the assay and identifica-
tion of almost all stem cell and progenitor popula-
tions, has been standardized. To advance the
quantitative use of colony-forming assays, the
ASTM International has published Standard Test
Method for automated colony-forming unit (CFU)
assays; Image Acquisition and Analysis Method
for Enumerating and Characterizing Cells and
Colonies in Culture has been developed (ASTM
InternationalF2944-12) [88]. Automated methods
for colony analysis have been applied in recent publi-
cations [4143,49,89].
The adoption and use of these standards and the
ongoing development of additional standards enu-
merating quantitative metrics that measure CQAs
for cellular therapies (product standards) will be
essential elements in advancing the field of cellular
therapy in general and particularly cellular therapies
for musculoskeletal disease [1720,87,90].Standardsvalue proposition and gaps, Richard
McFarland, PhD, MD
Existing consensus standards efforts in the area of
cellular therapies for musculoskeletal disease have
focused on the development of standardizing termi-
nology of various cell types, pre-clinical models and
analytical methods; in essence, they are focused on
measurement of the tissue-engineered product [91].
These are important areas for standardization for
academic reasons, but this focus is problematic for
transition of the space from an academic field with
the occasional artisanal product and widespread
non-clinically proven, off-label and practice of medi-
cine treatments to an industry with a wide array of
well-characterized and understood products avail-
able from which the practicing orthopedic surgeon
can chose according to their patient’s specific clinical
needs. Therefore, manufacturers should character-
ize, understand and, therefore, reproducibly control
the clinically relevant variabilities inherent in their
specific musculoskeletal medical product.
Currently, manufacturers must develop most
methods to control their manufacturing process and
product characterization procedures independentlybecause of a lack of such consensus standards. None-
theless, many of these unit operations and analytical
tests could be established and shared without jeopar-
dizing the intellectual property of any of the manu-
facturers. This situation results in increased cost to
developers in terms of time and resources when
everyone is forced to work independently. Fortu-
nately, this situation was recognized by the FDA,
National Institute of Standards and Technology
(NIST) and the regenerative medicine industry
group, Alliance for Regenerative Medicine (ARM),
and several steps have been taken to ameliorate it.
ARM spawned an independent non-profit from its
Standards and Technology Committee known as the
Standards Coordinating Body (SCB) whose mission
is to coordinate the accelerated advancement and
improved awareness of standards and best practices
that address the rapidly evolving needs of the global
regenerative medicine advanced therapy community.
The FDA and NIST are working collaboratively to
focus their respective resources to facilitate standards
efforts forward through many avenues, including
through efforts to interact and support SCB. For
example, the standards landscape report referenced
above and an approach for identification, prioritiza-
tion and feasibility analyses of standards gaps that
were due in September 2018 are the result of 21st
Century Cures Act mandated efforts. Over the
next few years, implementation of these processes
will provide new tools for transitioning the space
from almost entirely an academic and individual
practitioner-based pursuit to a growing industry with
numerous products and a vibrant R&D base.Insights from veterinary medicine
Regenerative medicine in equine and canine
musculoskeletal injuries, Laurie Goodrich DVM, PhD,
ACVS Diploma and Stephane Maddens, PharmD,
PhD, MBA
Biologically and clinically relevant animal models are
an essential component in pre-clinical screening for
virtually all biomaterials, drugs and cellular thera-
pies. However, veterinary practice in large and small
animals also represents the vanguard setting for clini-
cal application of many musculoskeletal therapies.
Naturally occurring injuries, such as degenerative
joint disease, OA and tendinopathy, are common
clinical settings with substantial demand for new
therapeutic approaches, particularly in the canine
and equine setting. Race horses represent an
intensely managed patient pool with a high incidence
of tendinopathy and whose return to service and rac-
ing performance are rigorously and quantitatively
measurable.
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or fat are among the most commonly used autolo-
gous cell therapies. Clinical use is climbing based on
reported efficacy in equine tendinopathy and articu-
lar joints [9294]. Doses of 10 to 20 million cells per
site are typically delivered. Regional perfusion via
intra-venous or intra-arterial delivery (without a
tourniquet) have been used [95], but intra-lesional
implantation appears to be most effective with
respect to clinical response and cell survival at the
site of the lesion [95]. In horses, multiple evidence-
based studies have suggested improved function and
athleticism and reduced re-injury rates compared
with non-treatment [9294].
MSC joint therapy has suggested success in cases
of meniscal disease, OA and cartilage damage
[94,96,97]. The value of injected MSCs in various
stages of joint disease is under intense investigation
and clinical studies are in progress. The safety and
efficacy of allogeneic MSCs are also being explored
with neonatal or adult tissues [98].
Many questions remain regarding cellular thera-
pies for musculoskeletal disease in the horse, includ-
ing the following: cell tissue source, allograft versus
autograft, dose, timing, disease severity and ana-
tomic location. The equine model is highly relevant
to each of these questions, as well as the assessment
of other biologics, used alone or in combination with
MSCs. Biologics such as PRP [99,100], Interleukin
Receptor Antagonist Protein (IRAP) [99,101] and
autologous protein solution (APS) [102] are also
extensively used in equine practice.
The health market for non-equine companion
animals (primarily canines) differs greatly from its
clinical human counterpart. It is much smaller in size
and care is not covered by a developed health insur-
ance system. Given these limitations, the veterinary
commercial industry has mainly focused on alloge-
neic MSC products with a high manufacturing scal-
ability. However, autologous MSC-based services
are often provided by academic centers.
Several characteristics may make MSCs from
neonatal tissues (placenta or cord-derived cells) pref-
erable to the use of allogeneic adult tissues or post-
natal tissues: (i) donors are healthy, (ii) harvest is not
invasive or compromising to the animal well-being,
(iii) there is low risk of biological hazard, (iv) donor
age is minimized and standardized, (v) neonatal
MSCs have a higher proliferation potential before
replicative senescence and (vi) neonatal MSCs have
a lower immunogenicity and a higher immunomodu-
lation potential [103,104]. Moreover, standardizing
source materials enables streamlining of regulatory
constraints, scale-up technologies (i.e., dynamic cul-
ture systems) and automation. These are critical
parameters in optimizing the product developmentprocess and limiting the risk of variation in product
composition and quality. All of these factors also
help to minimize fabrication cost. Lower costs will
make therapy more acceptable to a greater propor-
tion of practitioners and animal owners.
Prospective registries will be instrumental in
developing an improved understanding of the indica-
tions, contraindications, risks and benefits of cellular
therapies in veterinary practice in the same way that
they will benefit human clinical practice.Cell therapy
communicationnomenclature“The Tower
of Babel”
Defining the “MSC” populations, Massimo Dominici,
MD
Progenitor cells in bone marrow (BM) were
described in the 1960s by Alexander Friedenstein et
al. to explain the bone-forming potential of a rabbit
BM cell suspension [105]. The concept of rare, elu-
sive bone-forming cells was explored by many inves-
tigators over the past 50+ years using many
definitions and systems of nomenclature. Frieden-
stein et al. initially used the term “mechanocyte” for
the plastic adherent fibroblast-shaped mechanocyte
progenitors, due to their osteogenic (and, therefore,
eventually “mechanical”) properties [106,107]. Par-
allel investigations outlined the role of adherent BM-
derived cells in generating the stromal cells that were
necessary to provide the microenvironment needed
to support hematopoietic tissues in vitro [108].
These attributes of adherent fibroblastic cells
were merged in 1988 by Owen and Friedenstein who
defined culture-expanded BM-derived stromal cells
also as progenitors for the osteogenic lineage [109].
Building on the studies of the attributes of culture-
expanded marrow stromal cells, in 1991, Caplan
coined the term “mesenchymal stem cells” (MSCs),
using terms from embryonic development to reflect
the origin, multipotentiality as well as apparent pro-
liferative potential or “stemness” that progressively
prevailed the MSC “stromality” [110]. A few years
later, Prockop described culture-expanded cell popu-
lations with MSC properties from non-hematopoi-
etic tissues, including inducible expression of bone,
cartilage, fat and muscle markers in vitro [111]. Pit-
tenger et al. elegantly added deeper phenotypical
characterization [112].
A much higher level of stemness has been subse-
quently attributed to a possible subset of culture
expanded “MSCs” up to pluripotency, with almost
infinite proliferation and differentiation capacities
with a terminology shift to multipotent adult progen-
itor cells (MAPCs) [113]. Unfortunately, in vivo
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approaches revealed a low-engraftment rate and sub-
optimal therapeutic impacts [114].
As in vitro and in vivo data have accumulated
related to culture-expanded plastic adherent fibro-
blastic cells, the accuracy of the word “stem” has
been called into question [115]. At the same time,
ongoing work has become more focused on biologi-
cal functions more attributable to stromal and secre-
tory function than to differentiation [86,116,117].
Further work doubled back on history to include
the concepts of MSC heterogeneity among MSC
populations and variation in functional plasticity
[118]. Culture-expanded populations are not homo-
geneous, as initially assumed. They contain multipo-
tent populations together with less potent sub-types
whose nature, identity and ex vivo isolation/expan-
sion potential has yet to be defined. In addition,
MSCs retain variable attributes of stromal function
that can be influenced by environmental cues. All
this is certainly increasing the complexity, making it
difficult to unify a definition for culture-expanded
MSC populations.
The current nomenclature uses the term
“multipotent mesenchymal stromal cell” and is
based on position papers of almost 15 years ago
[86,117]. Characterizations by using new technol-
ogies for biological definition of culture-expanded
MSC populations are needed for an updated
nomenclature. Investigation also needs to be
traced back in vivo to unveil the heterogeneous
underlying colony-founding population(s) in
native tissues, from which culture expanded
“MSC” populations can be derived. Tangible
links to tissue-specific niches, tissue health (for-
mation and remodeling) and disease are needed.
All these approaches should be combined for
future MSC definitions rather than in a sterile
revision of the nomenclature alone.Tissue-specific “connective tissue progenitors”a
generalizable paradigm for tissue resident stem/
progenitors populations in musculoskeletal tissues, George
F. Muschler, MD
The concept of tissue-specific connective tissue pro-
genitor cells (CTPs) has been used as a valuable par-
adigm to explore and to define the heterogeneous
populations of stem and progenitor cells that are
present in vivo in native tissues, and to distinguish
the native cell populations that may be available for
point-of-care cell harvest and processing methods
from highly selected culture expanded populations
(e.g., MSCs) and cell lines that are commonly used
in research. This distinction is necessary for the
understanding of stem and progenitor cellfunction during tissue formation and remodeling,
and to identify and define the populations of cells
that may be targeted or used as cell source popu-
lations for tissue engineering and regenerative
therapies [17,3436,4143,88,119].
CTPs are defined as the heterogeneous popula-
tion of “tissue-resident” cells that can be harvested
from native tissues, induced to proliferate in vitro
and that can generate clonal progeny that can differ-
entiate into one or more connective tissue pheno-
types (e.g., bone, cartilage, adipocyte, fibroblast,
stromal cell or blood) [35,119]. The heterogeneous
population of cells that meets the criteria for a col-
ony-founding CTP includes true resting (G0) or self-
renewing stem cells. These true stem cells may be
present in one or more niches within a given tissue.
The CTP population also includes cells within native
tissues that may already be proliferating (transient
amplifying populations) or progenitor cells. In fact,
the dynamics of stem cell activation and downstream
transient amplifying populations (TAP) that precede
differentiation into a stable mature cell phenotype
predict that far more CTPs (colony founding cells)
will be derived from downstream TAP populations
than from true stem cells in any growing or remodel-
ing tissue [34,35,119].
The CTP paradigm assumes that each tissue will
contain one or more different CTP cell types repre-
senting different niches or compartments in that tis-
sue [35]. The hierarchy of cells that form the
connective tissue of blood have been best character-
ized [120,121]. The hierarchy of stem and progeni-
tor populations in BM began with Friedenstein and
Owen and others [109,122125]. CTPs with differ-
ent biological properties can be found in the marrow
space and the trabecular surface [41]. Some CTPs
are derived from aspirates of BM that retain hyalur-
onan (HA) on their surface, suggesting that they are
derived from a niche characterized by an HA-rich
extracellular matrix [43]. Bianco and Robey have
defined the “Skeletal Progenitor Cell” as a tissue-
specific CTP population on the trabecular surface,
which appear to express CD271 and CD146
[126,127]. Periosteum, synovium, cartilage, fat,
muscle, IVD and virtually all solid organs can be
sources of CTP populations. Perivascular cells, likely
among the pericyte population, are a source of CTPs
in all tissues, except cartilage [128]. However, evi-
dence suggests that not all pericytes are CTPs and
that the pericytes in different tissues have tissue-spe-
cific properties [126,127].
The prevalence of CTPs in native tissues varies
widely from patient to patient and from tissue to tis-
sue, from a mean of nearly one in 20 000 in native
BM to one in 2000 in healthy fat, synovium and car-
tilage [41,89,129,130]. CTPs, even in low numbers,
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biological potential that may be elicited or induced
by local or systemic drug delivery or local bioactive
biomaterials [4]. However, the low prevalence of
CTPs limits some tissue-engineering approaches.
This can be overcome by efficient harvest and proc-
essing methods that are designed to concentrate or
select CTPs for transplantation [1,9,14]. In many
cases, it may be desirable to isolate and culture
expand the progeny of CTPs in vitro to increase the
number of available cells and to select for or optimize
their biological properties prior to use. Application of
selected CTP populations include the following:
basic research in exploring the hierarchy of tissue-
specific CTPs and differentiation pathways, drug
discovery/screening and biofabrication of tissues for
re-implantation.
Under appropriate conditions, the culture-
expanded progeny of some CTPs may meet the crite-
ria that have been defined for a culture expanded
“MSC” population [86,117]. However, it is not clear
that MSC criteria are either necessary or specific for
prediction of biological potency or efficacy for any
particular application [89,131]. Defining the CQAs
for the culture-expanded progeny from the various
tissue-specific CTP populations for specific research
and clinical applications is a highly active area of
basic and translational research [132].The skeletal stem/progenitor cell: a tissue-specific stem/
progenitor cell population in BM, Pamela G. Robey,
PhD
There are two defining features of stem cells: (i) the
ability to functionally reconstitute the parenchyma of
a tissue, and (ii) the ability to self-renew (i.e., gener-
ate progeny that retain all of the biological properties
and potential of the original cell). Based on the early
work of Friedenstein and those that followed, it is
apparent that BM contains a population of clono-
genic, non-hematopoietic, rapidly adherent cells that
have the ability to form cartilage, bone, hematopoie-
sis supportive stroma and marrow adipocytes (func-
tional skeletal tissues), and that can self-renew based
on serial transplantation assays.
Culture-expanded cells that would have these
properties have commonly been labeled as
“mesenchymal stem cells,” grouping them together
with culture-expanded fibroblastic cells from many
tissues that have fibroblastic cell surface markers.
However, the use of MSC nomenclature in this way
is a misnomer. Mesenchyme is an embryological
term that is used to define embryonic connective tis-
sue that forms not only connective tissues, but alsoblood vessels and blood (no post-natal stem cell
retains this biological potential). Furthermore, bone
forms from three embryonic sources (neural crest,
ventral paraxial mesoderm of the sclerotome and
somatic lateral plate mesoderm). So-called MSCs
from non-skeletal tissues arise from other meso-
dermal specifications. As a result, colony-forming
cells in adult tissues do not arise from a single com-
mon ancestor, and are not a lineage. Furthermore,
when the progeny of colony forming units-fibroblasts
(CFU-Fs) are culture-expanded from different tis-
sues, their transcriptomes are indicative of their tis-
sue source, as is their differentiation capacity. The
culture-expanded cells derived from a selected popu-
lation of CD45¡/CD34¡/CD146+ cells will make
bone and cartilage. However, the progeny of
CD45¡/CD34¡/CD146+ muscle-derived cells do
not make bone or cartilage, but do make muscle.
These data reinforce the concept that CFU-Fs in
native tissues represent populations of tissue-specific
stem/progenitor cells. For these reasons, standards
for nomenclature will need to incorporate metrics
that enable differentiation of tissue-specific popula-
tions of colony-founding CFU-Fs. One of these
important subpopulations is the CD45¡/CD34¡/
CD146+ cell population on the surface of BM sinus-
oids that has been defined by the term skeletal stem/
progenitor cell. In spite of their differences in tran-
scriptome and differentiation capacity, many
CD146+ cells from different tissues have the ability
to associate with blood vessel walls, to form pericytes
and to remain quiescent until activated by an injury
or liberated by a bone turnover event [126,133,134].Editorial practiceschallenges and
responsibilities
The Journal of Bone and Joint Surgeryeditorial
practices, Thomas Bauer, MD, PhD
The potential benefits of cell therapy are commonly
discussed, many clinical trials are in progress and
hundreds of clinics offer “stem cell therapy” for vari-
ous musculoskeletal conditions. However, attempts
to judge and report cogently and definitively on the
efficacy of stem cell treatments have been largely
unsuccessful, in part because many details of cell
characterization, cell enrichment, cell processing and
indications for use have been missing in published
reports.
Piuzzi et al. [57] attempted to review the use of
BM aspirate concentrate in musculoskeletal disor-
ders but found that, of 46 reviewed articles, no single
study provided sufficient details to allow the methods
to be repeated. Only 30% of studies even provided
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processing. The authors proposed minimum infor-
mation that should be included in future publica-
tions.
Other publications have also suggested minimal
criteria needed to define the critical generalizable
parameters when discussing MSCs [86], stromal
cells from adipose tissue [135] and composition of
PRP [87]. All have emphasized the need for more
standardized content in cell therapy publications
[1720,90]. Murray et al. [87] compiled the results
of a Delphi consensus approach by e-mail, in which
a multidisciplinary group of investigators defined
Minimum Information for Studies Evaluating Bio-
logics in Orthopedics (MIBO), specifically related to
the use of PRP and MSCs, and have posted those
recommendations on line.
The mission of The Journal of Bone and Joint Sur-
gery (JBJS) is to improve musculoskeletal health
across the globe by delivering gold standard informa-
tion resources for clinicians, researchers and ortho-
pedic care teams. It strives to be the best place to
publish high-quality musculoskeletal research, and is
constantly seeking ways to improve publication qual-
ity and the peer review process. Through its web site,
JBJS offers links to the checklist developed by the
CONsolidated Standards of Reporting Trials
(CONSORT) Group [136], the format for cohort
studies suggested by the STrengthening the Report-
ing of OBservational studies in Epidemiology
(STROBE) panel [137], and meta-analysis criteria
from the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) Statement
[138,139]. JBJS has not yet developed a link to any
specific site that recommends minimal recom-
mended content with respect to cell therapy publica-
tions but, in principle, supports that concept.
Fulfilling such recommendations within the 3000
word limit for a JBJS manuscript may be difficult
but, in principle, the Journal would promote adher-
ence to reporting standards developed by the ISCT
or other appropriate organizations. Within limits,
standardized reporting should help maintain consis-
tency and the high quality that readers expect from
JBJS.Cytotherapyeditorial practices, John Barret, MD
Cytotherapy is the official journal of the ISCT. It was
created by the founding members of the ISCT in
1999 and its editors are ISCT members. This associ-
ation shapes the aims and scope of the journal to
conform to the expertise and purpose of the society.
Cytotherapy publishes reviews, commentaries, posi-
tion statements, white papers, original articles and
correspondence on all aspects of cell therapy inhumans from relevant laboratory science through
translational research to clinical implementation.
The journal is particularly a home for cell therapeu-
tics involving tissue-specific CTPs, culture-expanded
MSCs, other well-defined culture expanded cell pop-
ulations and immune cells. Cytotherapy prominently
features authoritative articles from ISCT leadership
(e.g., the Presidential Task Force on Unproven
Therapies, white papers on regulatory issues and
nomenclature). Aside from its association with the
ISCT, the journal serves a diverse readership. It is a
unique forum for publications on cell science, clini-
cal cell therapy trials, regulatory affairs, product
manufacture and commercialization of cell therapy.
The editor’s challenge is to serve this diverse
interest group, while maintaining an upward
momentum for the journal, as measured by the inter-
national breadth of its readership, its authority
among peer-reviewed journals and, of course, by its
impact factor. This diversity of responsibility can
cause dilemmas: not all society-related manuscripts
are well cited and this can be detrimental to the jour-
nal’s impact. Conversely, some papers of potential
impact are not handled because the topic is outside
the journal’s scope, in terms of reviewer expertise.
The rapid developments in new technologies
behoove the editor to constantly review, extend and
modify the journal scope in the light of important
developments (e.g., the burgeoning science of
cell exosomes). The rapid growth potential of cellu-
lar therapies for musculoskeletal care is another
example.
Fortunately for Cytotherapy, the field of cell ther-
apy is one of the most exciting and rapidly evolving
domains in the treatment of human disease. This
and the innovative and creative energy of our mem-
bers and readers are the essential forces that drive
our journal upwards.Research gapshidden gemscollaboration
opportunitiesstrategic initiatives
Obstacles to translation, Frank Barry, PhD
Over the past two decades a considerable body of
pre-clinical data was generated that suggested that
cellular therapy using culture-expanded MSCs
would find application in human medicine. How-
ever, that promise for human medicine has not yet
been fully realized. To date, MSC treatments have
received approval for only a handful of indications.
There are several major obstacles to translation that
still exist relating to understanding the mechanism of
the host response following transplantation. There is
also a general lack of technical competence in rigor-
ous, seamless, efficient and reproducible product
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long as these gaps are unfilled, it can be argued that
MSC therapy will not become a mainstream option
for patient care.
In broad terms, it is possible to identify a number
of major issues that hinder the therapeutic applica-
tion of MSCs. These include questions of fundamen-
tal biological importance such as the precise
therapeutic mechanism(s) of action, an understand-
ing of the interaction between transplanted cells and
cells of the host immune system and the nature,
accuracy and sensitivity of potency tests. For exam-
ple, it is apparent that many of the widely used
markers of MSCs, such as CD73 and CD105, lack
biological relevance and specificity and are not sensi-
tive indicators of phenotype or therapeutic activity
[89,131]. In addition, there are severe challenges in
terms of the logistics of manufacturing and supply,
including the use of biologically specific methods for
prospective isolation, scalable manufacturing sys-
tems and reliable cryopreservation. Further, the cur-
rent dependence on fetal bovine serum for cell
expansion represents a clear but unaddressed vulner-
ability. Of these, unravelling the therapeutic mecha-
nism of action seems to be the most pressing and, as
clinical proof of concept emerges, it will be possible
to achieve this. Only then will it be possible to devise
quantitative, disease-specific potency tests and quan-
titative CQAs for use as release criteria and in cali-
brating therapeutic dose.Cell and engineered tissue survey of ISCT members, Ivan
Martin, PhD
As cellular therapies in orthopedics become more
widespread for a variety of indications and modali-
ties, it is challenging to maintain a clear perspective
on the effectiveness of the treatments performed,
and to provide a basis of objectivity and transparency
in defining developing trends.
Since 2008, the ISCT, the European Chapter of
the Tissue Engineering and Regenerative Medicine
International Society (TERMIS-EU), the Interna-
tional Federation for Adipose Therapeutics
(IFATS), the International Cartilage Repair Society
(ICRS) and the European group for Blood and Mar-
row Transplantation (EBMT) have established an
instrument to survey and report on the status of cell
and engineered tissue therapies in Europe and neigh-
boring Eurasian countries [140]. The program col-
lects data of treated patients sorted by specific
therapeutic indications, cell/tissue donor types, proc-
essing and delivery modes, without reference to the
clinical outcome. The information is thus comple-
mentary to published results or to the results avail-
able through public clinical trial databases.Last year’s report, related to patients treated in
2015, captured data from 178 clinical teams, related
to the treatment of 3686 individuals [141]. The mus-
culoskeletal/rheumatological field represented 32%
of all treatments. Cartilage repair was the most fre-
quent indication (53%), followed by reconstructive
surgery (19%) and bone repair (13%). Autologous
cells were used in 94% of these patients. Culture-
expanded MSCs were used in 40% of bone repair
and in 19% of cartilage repair procedures. Chondro-
cytes were used in 37% of bone procedures and in
61% of cartilage repair procedures.
This concise snapshot outlines the type of infor-
mation that can be gathered from the cell and engi-
neered tissue survey. A yearly report acknowledges
the participating teams. The ISCT hosts the instruc-
tions and forms required to participate [142] and
supports a continuous development of the program,
towards extension to other geographical areas and
inclusion of additional information (e.g., metrics of
cell manufacturing and context of clinical treat-
ment).Cell therapypoint-of-care quality control and process
metricsfeasibility and necessity, David Karli, MD,
MBA
Autologous, point-of-care (POC) therapies, includ-
ing PRP and BM Cell Concentrate (BMC), have
continued to increase in clinical use. The over-
whelming majority of this care has involved
bench-top processing density separation units. How-
ever, the process does not include direct cell count-
ing or any other product release criteria as quality
control metrics.
Assay of cellular composition is a critical missing
element in the responsible advancement and assess-
ment of these therapies. A recent review of published
clinical studies using BMCs for orthopedic applica-
tions revealed that only 30% of the studies reported
on the number of cells injected. When cell concen-
tration or composition was reported, the approach
was not standardized with respect to counting
method [57]. Despite this inconsistency and gap in
the literature, examination of those studies that have
quantified cell counts suggest that therapeutic effi-
cacy might be linked to both cellular and platelet
concentrations. This reinforces the clinical need for
measurement.
Methods to obtain real-time validated cell and
platelet counts are available for peripheral blood and
PRP preparations using modern automated hemoa-
nalyzers and manual processing techniques. How-
ever, the substantial heterogeneity of BM aspirates
(BMAs) present a challenge to the validation of accu-
rate and automated hemoanalyzer measurements of
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automated analysis of BMA and BMC preparations.
CFU assays to measure CTP prevalence and flow
cytometry assays using markers of hematopoietic
stem cells (e.g., CD34) and putative markers of CTP
subpopulations (Hyaluronan and CD146) are also
under investigation. However, colony assays and
flow cytometry methods require technical expertise
and add cost, but are generally available at academic
medical centers.
Systems and platforms for improved collection
and integration of clinical data and quantitative
assessment of the composition of cellular therapies
are needed. Cost-effective systems can include, at a
minimum: (i) patient demographic data; (ii) clinical
diagnosis, site and severity data; (iii) cellular compo-
sition (at a minimum hemoanalytic data); and (iv)
clinical outcomes data (i.e., patient-reported general
health and diseases-specific metrics). Prospective
scalable practice databases are essential tools to
establish formal clinical registries and consortia
needed to examine cellular therapies in prospective
cohorts or randomized trials.
For profit and non-profit electronic resources
exist and are being piloted to collect clinical baseline
data as well as follow-up data. Strategic industry and
multicenter collaborations using standardized clini-
cal and product metrics will allow capture of the
larger datasets needed to provide the statistical
power needed to objectively compare the efficacy of
different approaches for specific clinical indications.Development of orthopedic biological registries and
clinical trials network, Constance Chu, MD
The disease burden of serious and disabling muscu-
loskeletal conditions, such as OA and degenerative
tendinopathy, are high, and restorative treatments
are limited. These realities create strong interest for
patients to seek new and often unproven therapies.
Presently, the clinical use of biologics such as PRP or
cell-based therapies greatly outpaces the evidence.
Consensus recommendations from a recent Ameri-
can Academy of Orthopedic Surgeons (AAOS)
work-group include the strong recommendation that
orthopedic biological registries and clinical trial net-
works be established and supported [143]. Only
through collaborative effort can the high-quality evi-
dence that clinicians and patients need become avail-
able in a timely and cost-effective manner [144].
The orthopedic community has several estab-
lished registry models for joint replacement, anterior
cruciate ligament reconstruction and other condi-
tions that have contributed important clinical infor-
mation on practice patterns, patient outcomes and
clinical quality based on post-market performance ofimplants and grafts [145,146]. Leveraging these
pathways into a biologics registry could similarly
contribute ‘real world’ clinical data on the use and
outcomes of biologics.
Biologics that are derived from the patient’s own
cells or tissues present the additional challenge of
wide variability in composition and bioactivity [147].
In this setting, assessment of processing quality and
product biological effects necessitate collection and
analysis of samples collected before and after any
processing. For example, in the evaluation of PRP,
standardized automated laboratory analysis of the
complete blood count (CBC) for samples of the
patient’s whole blood collected to prepare PRP as
well as the finished PRP would allow for determina-
tion as to what degree the platelets were concen-
trated. This information could then be used to
evaluate quality and consistency of the processing
device as well as the relationship between platelet
concentration and clinical outcomes.
The non-cellular and proteomic composition of
the end product is also highly variable between
patients and between samples collected at different
times. Variability in proteomic composition and bio-
activity likely impact clinical effect. Establishment of
biorepository-linked registries where biospecimens
are linked to clinical data can support subsequent
proteomic analyses to potentially identify proteins
and biomarkers that are predictive of clinical out-
comes.
Several observational consortia [148,149], as well
as a multicenter clinical trials pilot study [150], dem-
onstrate the feasibility of this approach. A framework
for systematic gathering and analyses of patient-
reported outcomes, establishing a biorepository, as
well as development of standardized functional and
imaging outcome metrics have been established
[144]. Appropriate infrastructure and incentives will
be needed to motivate both physician and patient
participation in both sample analysis and outcome
reporting.Summary
This Signature Series Symposium achieved its core
objectives. A forum of multidisciplinary thought
leaders was gathered, including basic and transla-
tional scientists, clinicians, regulatory experts, edi-
tors and reviewers from the flagship journals in
orthopaedic surgery and cellular therapies. The sta-
tus of the field was rigorously assessed. Key chal-
lenges and opportunities were defined in the areas of:
marketing of unproven therapies, current clinical
effectiveness and value, regulatory affairs, standards
development, clarity in nomenclature and
Proceedings 1395transparency in publication and enabling clinical net-
works and registries.
Through the symposium a broad-based musculo-
skeletal community has been initiated within the
ISCT with the mission to continue in its effort to
enable, engage and expand this leadership forum
within ISCT, in collaboration with other relevant
groups and societies, to make musculoskeletal cellu-
lar therapies a safe and effective reality for patients
and a fertile ground for rapid and effective innova-
tion, communication and dissemination of informa-
tion that advances the field.Acknowledgments
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